Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Cookies
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Monopar Therapeutics (MNPR) · oqro.io/stocks/MNPR · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
Questions about Monopar Therapeutics insider trading
Have Monopar Therapeutics insiders bought shares recently?
No open-market purchase by an insider of Monopar Therapeutics was filed in the last 90 days. The latest on record was on Oct 30, 2024.
How often do Monopar Therapeutics insiders buy and sell shares?
Since 2019, Monopar Therapeutics insiders reported 18 open-market purchases and 25 sales on Forms 4 and 5, with purchases in 3 different years, most recently 2024.
Who is selling Monopar Therapeutics stock?
In the last 90 days, 4 insiders of Monopar Therapeutics (MNPR) reported 15 open-market sales worth $3.72M in total on SEC Form 4. The largest seller by value was Chandler Robinson, with $2.56M. Many insider sales follow a plan set in advance or cover taxes on stock awards; the filing says what was sold, not the reason.
Do members of Congress trade MNPR?
No trade in Monopar Therapeutics (MNPR) was disclosed by a member of Congress in the last 12 months.
Where does this data come from?
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
−16.9% (−$14.00) from Nov 20, 2025 to Nov 20, 2026 · adjusted daily closes
Adjusted close went from $83.00 on Nov 20, 2025 to $69.00 on Nov 20, 2026 (−16.9%). Disclosed in this range: 0 insider trades, 15 pre-arranged insider sales, 0 Congress trades, and 5 13F position changes for 3 quarters ending in it.
$40$80$100$120$140$69.00
DecJan 2026FebMarAprMayJunJulAugSepOctNov
13F holdings, by quarter end
Insider and Congress marks sit on the trade date stated in the filing; solid is a purchase, hollow a sale. A number means several trades too close to tell apart at this range: pick a shorter range or open it for the list. Fund 13F reports are quarter-end snapshots filed up to 45 days later, so they are shown under the chart across the quarter they describe, not on the price line. Congress amounts are official ranges; mark size uses the lower bound. Past moves are not a forecast.Show the 15 trades in this range as a list
Kim R Tsuchimoto, Director · 3 pre-arranged insider sales, about $206Ktraded Nov 4, 2026, filed Nov 5, 2026
Raymond Anderson, Director · 4 pre-arranged insider sales, about $215Ktraded Nov 2, 2026, filed Nov 5, 2026
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Pharmaceutical Preparations company based in Wilmette, Il.
Last 12 months
−16.9%
S&P 500 +5.7% over the same dates
Market value
$468M
Close of Nov 20, 2026 × shares outstanding (per ADS where it applies)
S&P 500 +5.7% over the same dates. Prices adjusted for splits and dividends.
Short interest: 1.1M shares sold short (16.3% of shares outstanding), −2.2% vs the previous count, 8.8 days of normal trading to buy them back. FINRA, as of Oct 30, 2026.
Latest results: quarter ending Sep 30, 2026
Revenue
$0
Free cash flow, last 12 months
—
Cash from operations minus capital spending
Net debt
—
Debt —, cash $52.6M, at Sep 30, 2026
Net income, last 12 months
−$20.6M
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Nov 12, 2026.
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
The year in the managers' words
Every annual report has a section where the company's managers explain the year's results (Item 7, Management's discussion and analysis). In this report it runs to about 8,000 words.
From “Overview”, in the company's words
We are a clinical-stage biopharmaceutical company with late-stage ALXN1840 for Wilson disease, and radiopharmaceutical programs, including Phase 1-stage MNPR-101-Zr for imaging advanced cancers along with Phase 1a-stage MNPR-101-Lu and late preclinical-stage MNPR-101-Ac225 for the treatment of advanced cancers. We leverage our scientific and clinical experience to help reduce the risk and accelerate the clinical development of our drug product candidates.
What the section covers (33 headings)
Overview
Financial Status
ALXN1840 for Wilson Disease
MNPR-101 for Radiopharmaceutical Use, Development Update
Our Strategy
Revenues
Recently Issued and Adopted Accounting Pronouncements
Critical Accounting Policies and Use of Estimates
Clinical Trials Accruals
Stock-Based Compensation
Pre-funded Warrants
Results of Operations
Comparison of the Years Ended December 31, 2025, and December 31, 2024
Research and Development (“R&D”) Expenses
And 19 more headings in the filing.
Source: SEC EDGAR, Form 10-K filed Mar 27, 2026. The quote is the opening of the managers' discussion, cut at a sentence; the word count is estimated from its length. Not investment advice.
When insiders usually buy
Last results
Nov 12, 2026
Within the 30 days after it, until Dec 12, 2026
Next results, expected
Not announced
Purchases after results
54%
7 of 13 insider purchases since 2020 came within 30 days after a results announcement
From Monopar Therapeutics's own results filings (8-K Item 2.02) and its insiders' Forms 4 and 5. Many companies only let insiders trade in a period after results; OQRO does not know Monopar Therapeutics's policy and only shows the pattern in the filings. A purchase made long after results, at a company whose insiders usually buy right after them, is marked “Bought outside the usual window”.
OQRO Intelligence
Written by OQRO's software from the last 12 months on record · Nov 19, 2026
Insiders. In the 12 months to Nov 19, 2026, insiders of Monopar Therapeutics filed 0 open-market purchases (about $0, in 0 filings, by 0 people) and 15 open-market sales (about $3.72M, in 4 filings, by 4 people). One Form 4 can list many transactions. In the 12 months before that, they filed 0 open-market purchases (about $0, in 0 filings) and 5 open-market sales (about $37.9M, in 5 filings). (Monopar Therapeutics on OQRO)
Funds and stakes. Fund 13F filings recorded in the 12 months show 5 new or larger positions and 0 smaller or closed positions. A 13F is a snapshot of holdings at the end of a quarter.
Contracts, lobbying and filings. FINRA short interest for MNPR on the settlement date of Oct 30, 2026 was 1,103,516 shares (-2.22% on the previous report), about 8.8 days of average volume. In 13F filings for the quarter ended Jun 30, 2026, the largest positions that grew: Orbimed Advisors LLC (new position); Candriam S.C.A. (new position); the largest that shrank: Polar Capital Holdings Plc (reduced, 12,057 shares). A 13F is a quarter-end snapshot with no trade date.
Company reports, price and press. Monopar Therapeutics filed a Form 8-K on Nov 12, 2026 (Item 2.02) that OQRO classes as: reported its results. Monopar Therapeutics filed a Form 8-K on Aug 12, 2026 (Item 2.02) that OQRO classes as: reported its results.
Who holds it. 96 funds reported a stake in Monopar Therapeutics in their 13F for Q2 2026. The largest by value: Jupiter Topco LLC (21.1% of the value reported), RA CAPITAL MANAGEMENT, L.P. (10.7% of the value reported), BlackRock, Inc. (5.6% of the value reported).
Insider buying and selling since 2019
Insiders of Monopar Therapeutics reported 18 open-market purchases and 25 sales since 2019; purchases in 3 different years, most recently 2024.
Year
Bought
Sold
2026
—
$3.72M15×15 trades
2025
—
$37.9M5×5 trades
2024
$125K11×11 trades
—
2022
$50K
2×2 trades
—
2021
—
$1.83M5×5 trades
2019
$6.01M5×5 trades
—
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
Source: SEC Schedules 13D and 13G, which anyone owning more than 5% of a class of stock must file. A 13D filer may seek to influence the company; a 13G filer is passive. Filings before December 2024 are free text and read from their cover page: a percent or share count that is not stated plainly is left blank. Each line links to the filing.
1 certified in FY2026 Q3, vs 0 a year earlier. 1 position in total, median offered wage $98K a year.
CMC Operations Associate · 1
Labor condition applications for H-1B workers certified by the Department of Labor, counted by decision date (FY2026 Q3: Apr 1, 2026 to Jun 30, 2026, the latest quarter published). A certified application is a step before a visa petition, not a hire or a visa, and one application can cover several positions. Matched by employer ID number or name.
Things to keep in mind. These are counts of the filings OQRO holds, in the days they were filed; a busy or quiet month does not say why. A Form 4 reports a transaction; it does not say why it was made, and some follow trading windows or pre-arranged plans. Congress reports give only amount ranges and arrive after the trade. Total compensation in a proxy statement counts stock and option awards at their grant-date value, not what was sold.
Facts used for this text
Every number, name, date and link in the text above comes from this list; software checks that before the text is stored. This text was assembled directly from the facts, without a language model.
Insiders
In the 12 months to Nov 19, 2026, insiders of Monopar Therapeutics filed 0 open-market purchases (about $0, in 0 filings, by 0 people) and 15 open-market sales (about $3.72M, in 4 filings, by 4 people). One Form 4 can list many transactions.
In the 12 months before that, they filed 0 open-market purchases (about $0, in 0 filings) and 5 open-market sales (about $37.9M, in 5 filings).
The largest sale: Chandler Robinson, Chief Executive Officer, about $911K, filed Sep 29, 2026.
Funds and stakes
Fund 13F filings recorded in the 12 months show 5 new or larger positions and 0 smaller or closed positions. A 13F is a snapshot of holdings at the end of a quarter.
Contracts, lobbying and filings
FINRA short interest for MNPR on the settlement date of Oct 30, 2026 was 1,103,516 shares (-2.22% on the previous report), about 8.8 days of average volume.
In 13F filings for the quarter ended Jun 30, 2026, the largest positions that grew: Orbimed Advisors LLC (new position); Candriam S.C.A. (new position); the largest that shrank: Polar Capital Holdings Plc (reduced, 12,057 shares). A 13F is a quarter-end snapshot with no trade date.
For fiscal 2025, the company's proxy statement reported total compensation of $10.6M for its principal executive officer, and an average of $2.32M for the other named executive officers.
Company reports, price and press
Monopar Therapeutics filed a Form 8-K on Nov 12, 2026 (Item 2.02) that OQRO classes as: reported its results.
Monopar Therapeutics filed a Form 8-K on Aug 12, 2026 (Item 2.02) that OQRO classes as: reported its results.
Monopar Therapeutics filed a Form 8-K on May 14, 2026 (Item 2.02) that OQRO classes as: reported its results.
Press coverage listed by Finnhub: "Monopar Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Updates" (Yahoo, Nov 12, 2026).
Press coverage listed by Finnhub: "Monopar to Present at AASLD, The Liver Meeting® 2026: Phase 3 FoCus Baseline Data and ALXN1840 Molybdenum Safety Data" (Yahoo, Nov 2, 2026).
Press coverage listed by Finnhub: "Monopar Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates" (Yahoo, Aug 12, 2026).
MNPR closed at $70.75 on Nov 18, 2026, the last session on or before the end of the period.
From Oct 19, 2026 to Nov 18, 2026, the close moved from $71.47 to $70.75, a change of −1.0%.
Who holds it
96 funds reported a stake in Monopar Therapeutics in their 13F for Q2 2026. The largest by value: Jupiter Topco LLC (21.1% of the value reported), RA CAPITAL MANAGEMENT, L.P. (10.7% of the value reported), BlackRock, Inc. (5.6% of the value reported).
Things to keep in mind
These are counts of the filings OQRO holds, in the days they were filed; a busy or quiet month does not say why.
A Form 4 reports a transaction; it does not say why it was made, and some follow trading windows or pre-arranged plans. Congress reports give only amount ranges and arrive after the trade.
Total compensation in a proxy statement counts stock and option awards at their grant-date value, not what was sold.
An 8-K item says what the company reported, not what it means for the share price.
Headlines are listed as published by the outlets; OQRO has not checked them and does not summarise articles.
Share price moves are listed as context only; the filing does not explain them and other news can move a price.
This describes public filings. It is not investment advice.
Written by software from the filings listed below · Nov 21, 2026
Insiders. In the 30 days to Nov 21, 2026, insiders of Monopar Therapeutics filed 0 open-market purchases and 8 open-market sales (about $505K, in 2 filings, by 2 people). One Form 4 can list many transactions. In the 30 days before that, they filed 0 open-market purchases and 7 open-market sales (about $3.22M, in 2 filings). (Monopar Therapeutics on OQRO)
Contracts, lobbying and filings. FINRA short interest for MNPR on the settlement date of Oct 30, 2026 was 1,103,516 shares (-2.22% on the previous report), about 8.8 days of average volume. In 13F filings for the quarter ended Jun 30, 2026, the largest positions that grew: Orbimed Advisors LLC (new position); Candriam S.C.A. (new position); the largest that shrank: Polar Capital Holdings Plc (reduced, 12,057 shares). A 13F is a quarter-end snapshot with no trade date.
Company reports, price and press. Monopar Therapeutics filed a Form 8-K on Nov 12, 2026 (Item 2.02) that OQRO classes as: reported its results. The press release filed with it is titled: "Monopar Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Updates"
Things to keep in mind. These are counts of the filings OQRO holds, in the days they were filed; a busy or quiet month does not say why. A Form 4 reports a transaction; it does not say why it was made, and some follow trading windows or pre-arranged plans. Congress reports give only amount ranges and arrive after the trade. Total compensation in a proxy statement counts stock and option awards at their grant-date value, not what was sold.
Facts used for this text
Every number, name, date and link in the text above comes from this list; software checks that before the text is stored. This text was assembled directly from the facts, without a language model.
Insiders
In the 30 days to Nov 21, 2026, insiders of Monopar Therapeutics filed 0 open-market purchases and 8 open-market sales (about $505K, in 2 filings, by 2 people). One Form 4 can list many transactions.
In the 30 days before that, they filed 0 open-market purchases and 7 open-market sales (about $3.22M, in 2 filings).
The largest sale: Raymond Anderson, Director, about $105K, filed Nov 5, 2026.
Contracts, lobbying and filings
FINRA short interest for MNPR on the settlement date of Oct 30, 2026 was 1,103,516 shares (-2.22% on the previous report), about 8.8 days of average volume.
In 13F filings for the quarter ended Jun 30, 2026, the largest positions that grew: Orbimed Advisors LLC (new position); Candriam S.C.A. (new position); the largest that shrank: Polar Capital Holdings Plc (reduced, 12,057 shares). A 13F is a quarter-end snapshot with no trade date.
For fiscal 2025, the company's proxy statement reported total compensation of $10.6M for its principal executive officer, and an average of $2.32M for the other named executive officers.
Company reports, price and press
Monopar Therapeutics filed a Form 8-K on Nov 12, 2026 (Item 2.02) that OQRO classes as: reported its results.
The press release filed with it is titled: "Monopar Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Updates"
Its announcing sentence reads: "Monopar Therapeutics Inc. ("Monopar" or the "Company") (Nasdaq: MNPR), a clinical‐stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced third quarter 2026 financial results and provided business updates."
Press coverage listed by Finnhub: "Monopar Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Updates" (Yahoo, Nov 12, 2026).
Press coverage listed by Finnhub: "Monopar to Present at AASLD, The Liver Meeting® 2026: Phase 3 FoCus Baseline Data and ALXN1840 Molybdenum Safety Data" (Yahoo, Nov 2, 2026).
MNPR closed at $69.00 on Nov 20, 2026, the last session on or before the end of the period.
From Oct 21, 2026 to Nov 20, 2026, the close moved from $72.35 to $69.00, a change of −4.6%.
Off-exchange trading: 40.9% of the shares traded over the latest 4 published weeks changed hands away from the exchanges (31.4% on ATS, 9.5% with other brokers), above its 26-week average of 33.3%. Weeks of Sep 21 to Oct 16, 2026.
These are counts of the filings OQRO holds, in the days they were filed; a busy or quiet month does not say why.
A Form 4 reports a transaction; it does not say why it was made, and some follow trading windows or pre-arranged plans. Congress reports give only amount ranges and arrive after the trade.
Total compensation in a proxy statement counts stock and option awards at their grant-date value, not what was sold.
An 8-K item says what the company reported, not what it means for the share price.
Headlines are listed as published by the outlets; OQRO has not checked them and does not summarise articles.
Share price moves are listed as context only; the filing does not explain them and other news can move a price.
This describes public filings. It is not investment advice.
Week of Apr 20ATSOther off-exchangeFull height = all shares tradedWeek of Oct 12
Largest ATS: SIGMA X2 (15.0%), UBS ATS (11.1%), ONECHRONOS (6.4%), as a share of this stock's ATS volume over the same 4 weeks.
An ATS, often called a dark pool, is a private trading venue run by a broker where orders are not shown publicly before they trade. Other off-exchange trades are mostly retail orders filled by wholesale brokers. A high share is common and says nothing by itself about where the price goes. FINRA OTC Transparency data, published 2 weeks after each week for the largest stocks and 4 weeks for others; total volume from our daily price data.
Risk factors in the annual report
Latest annual report filed Mar 27, 2026, compared with the one filed Mar 31, 2025. Read the filing
No longer listed (1 heading from the year before)
Holders of the shares of our common stock will have no control of our operations or of decisions on major transactions.
Legal proceedings (Item 3)
We are currently not, and to date have never been, a party to any adverse material legal proceedings.
Source: SEC EDGAR, Form 10-K filed Mar 27, 2026. Headings are the titles the company gives each risk; OQRO compares them with the year before by their words, so a heading that was reworded a lot shows up as both new and no longer listed. Companies list the risks they face, not forecasts.
Since Nov 19, 2025, MNPR is down 16.9% and the index fund is up 4.1%: 21 points behind the market. Traders call a stock that beats the index over a period a relative-strength leader.
How much MNPR moves
A usual day
±2.2%Half of the sessions moved less than this, half moved more.
Daily range (ATR 14)
6.6%How far the price usually travels in a session, the gap from the day before included. Wilder's 14-session average.
Largest one-day fall
−11.2%Feb 4, 2026
Largest one-day rise
+19.1%Jun 23, 2026
Deepest fall of the year
−46.5%From the close of Aug 19, 2026 to Nov 2, 2026.
Days of 5% or more
38Out of 252 sessions, in either direction.
Beta 1.3(1 year vs SPY)
End-of-day prices. These figures describe the past year and say nothing about what comes next. Beta: how much the stock moved, on average, for each 1% move of the S&P 500 fund over 251 trading days (1 = in step with it).